<DOC>
	<DOCNO>NCT00409994</DOCNO>
	<brief_summary>Investigating safety activity Rapamycin , administer preoperative radiotherapy patient operable colorectal carcinoma . The phase I dose escalation study perform three step ( 2 , 4 6 mg ) . Patients enter phase II follow tolerable treatment regimen patient phase I study .</brief_summary>
	<brief_title>Safety Study Rapamycin Administered Before During Radiotherapy Treat Rectum Cancer</brief_title>
	<detailed_description>Treatment regimen Phase I A daily dose Rapamycin take 13 day . At step 1 dose 2 mg give day ; step 2 dose 4 mg give day ; step 3 dose 6 mg give day . Preoperative radiotherapy ( 5x 5 Gy ) administer day 8-12 , follow TME-surgery day 15 . Phase II A daily dose 6 mg Rapamycin take 14 day ( unless optimal dose find phase I study low ) . Preoperative radiotherapy ( 5x 5 Gy ) administer day 9-15 , follow TME-surgery 7-8 week post RT . Sample size Phase I dose-escalation study Minimum 3 eligible patient per step , maximum 6 eligible patient per step . Phase II A total 47 patient enter part study .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically proven rectum cancer UICC TNM IIII WHO performance status 02 Less 10 % weight loss last 6 month No recent ( &lt; 3 month ) severe cardiac disease Normal serum bilirubin serum creatinin Concurrent chemotherapy radiation History prior pelvis radiotherapy Recent ( &lt; 3 month ) myocardial infarction Uncontrolled infectious disease Concurrent medication know inhibitor CYP3A4 susceptible increase Rapamycin blood concentration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>M-tor inhibitor</keyword>
	<keyword>Rapamycin</keyword>
</DOC>